Due to fedratinib's significant GI side effect profile and the logistical difficulty of measuring thiamine levels, clinicians should proactively provide patients with thiamine supplements, anti-emetics, and anti-diarrheal therapies. Instructing patients to take the drug with food can also help mitigate GI toxicity.

Clinicians can reassure myelofibrosis patients that the drop in hemoglobin often seen when starting ruxolitinib does not carry the same negative prognostic weight as anemia caused by the disease itself. This distinction is crucial for managing patient expectations and continuing effective therapy despite initial side effects.

In patients with diffuse bone metastases, it is crucial to determine if cytopenias (low blood counts) are caused by the treatment or by the cancer infiltrating the bone marrow. This distinction is critical for making correct decisions about dose modifications or treatment holds.

To minimize steroid toxicity, a thrombopoietin receptor agonist (TPORA) should be the immediate second-line therapy for ITP patients who fail their initial course of corticosteroids. There is no need to trial multiple other therapies before considering a TPORA.

To manage the high risk of neutropenia with sacituzumab govitecan, prophylactic growth factor (G-CSF) use is becoming standard clinical practice. This is particularly true after the Day 8 administration. For some populations, like Asian patients, it is considered mandatory from the start, sometimes with a dose reduction.

For myelofibrosis patients with both anemia and splenomegaly, a practical approach is to start with ruxolitinib for its superior symptom control. If the subsequent anemia is not well-tolerated, switching to momelotinib allows for a more informed, personalized decision based on the patient's experience with both agents.

Despite Belzutafan's clinical successes, effective biomarkers for patient selection are almost non-existent. Experts anticipate a significant increase in understanding over the next 12-24 months from correlative studies, which will likely reveal novel gene expression and tissue-based markers beyond obvious candidates like serum EPO.

Eltrombopag is a potent iron chelator that can cause or worsen iron deficiency. In ITP patients with existing iron deficiency, alternative TPO receptor agonists like avatrombopag or romiplostim, which do not chelate iron, should be used instead.

Clinicians should interpret anemia in myelofibrosis patients on JAK inhibitors based on its timing. Anemia in the first 16 weeks is an expected on-target effect. In contrast, new anemia in a patient on a stable dose is a warning sign that may indicate disease progression, warranting further investigation.